Eisai has reported preliminary results of the Phase 3 study of Halaven versus capecitabine (Xeloda) in patients with locally advanced or metastatic breast cancer.

The open-label, randomised study failed to meet the pre-specified criteria for either of the co-primary endpoints of overall survival (OS) and progression-free survival (PFS).

President of Eisai Oncology Product Creation Unit, Kenichi Nomoto, said that the study was a head-to-head comparison designed to show superiority against a commonly used drug approved in an earlier line of therapy than the FDA-approved indication for Halaven.

"We will look closely at the full data results to determine meaningful learnings for the medical community," Nomoto added.

"Eisai remains committed to evaluating the safety and efficacy of eribulin in patients living with locally advanced or metastatic breast cancer, an area of significant unmet medical need."

The trial included 1,102 women with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes either in the (neo) adjuvant setting or for locally advanced or metastatic disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study observed a trend toward improved OS for patients who received Halaven compared with capecitabine, but the improvement was not statistically significant. No difference was reported in PFS.

The company is conducting a detailed analysis of the data, such as the secondary endpoints and subgroups pre-specified in the study protocol, and is planning to discuss the data with health authorities for regulatory filing.

Adverse events observed in the two-parallel-arm, multicentre study were consistent with the known safety profile of Halaven found in the full prescribing information.

Halaven, a natural product that was isolated from the marine sponge Halichondria okadai, is indicated for patients with breast cancer who have received at least two other types of anticancer medicines for their breast cancer once it has spread.

Image: Eisai’s Phase 3 breast cancer study of Halaven did not meet the pre-specified criteria for either of the co-primary endpoints of OS and PFS. Photo courtesy of: ja.wikipedia.